Executive Vice President and Chief Commercial Officer, BioMarin
Jeff Ajer joined BioMarin in 2005 and is the Executive Vice President and Chief Commercial Officer. He has served as Chief Commercial Officer of Biomarin since 2012. Previously, Mr. Ajer served as BioMarin’s Vice President of Commercial Operations, The Americas, where he had responsibility for commercial operations throughout the Americas and led product marketing, reimbursement, and sales operations for BioMarin. Since joining as one of the first sales and marketing employees, Mr. Ajer has played a leadership role in establishing BioMarin’s successful commercial infrastructure and global footprint, shaped the launches and growth strategies for the company’s three key commercial products for rare diseases, and led commercial planning for late-stage pipeline programs. Prior to BioMarin, Mr. Ajer served as Vice President, Global Transplant Operations at Genzyme Corporation. Mr. Ajer’s experience prior to Genzyme includes roles in sales, marketing and operations at SangStat Medical Corporation and ICN Pharmaceuticals. Mr. Ajer received a B.S. in chemistry and an M.B.A. from the University of California, Irvine.
Dr. Rajeev Dadoo
Partner, SR One
Rajeev Dadoo joined SR One in 2003 and is an alum of the Kauffman Fellows Program. He serves as a director on the boards of IlluminOss Medical, NeuroTherapeutics Pharma and Synovex and is an observer on the boards of Concert Pharmaceuticals. Rajeev has been involved with SR Ones investments in Cydex, Hypnion, Predix Pharmaceuticals, Rib-X Pharmaceuticals, Octoplus, Trigen, Nucleonics, and Pinnacle Pharmaceuticals. In addition to his role at SR One, Rajeev spent time with the Competitive Excellence group within GSK working on company-wide strategic projects for GSKs Corporate Executive Team. Prior to SR One, Rajeev worked at Genentech, where his role included technology and clinical development, and at Bio-Rad Laboratories in a product development role. In addition, Rajeev has worked at Genome Therapeutics in the business development role. Rajeev was a co-founder of Unimicro Technologies, a company that was created to develop and commercialize instrumentation for biomedical analysis. Rajeev received his BA degree in Chemistry and Mathematics from Knox College, his MBA from the Wharton School of the University of Pennsylvania, and his PhD in Chemistry from Stanford University.
Dr. Carl L. Gordon
Carl Gordon is a founding Partner and Co-Head of Global Private Equity at OrbiMed. Dr. Gordon is active in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Dr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a bachelor’s degree from Harvard College. Carl was included on the Forbes Midas List of top venture capital investors in 2014.
Dr. Isaac Manke
Public Equity Partner, New Leaf Venture Partners
Isaac Manke, Public Equity Partner, joined New Leaf Venture Partners in 2009. Prior to joining New Leaf, Isaac was an Associate in the Global Biotechnology Equity Research group at Sanford C. Bernstein. Previously, Isaac worked as an Associate in the Biotechnology Equity Research group at Deutsche Bank. Prior to joining Deutsche Bank, Isaac was a Senior Analyst at Health Advances, a biopharmaceutical and medical device strategy consulting firm in Massachusetts. Isaac received a B.A. in Biology and a B.A. in Chemistry at Minnesota State University (Moorhead), and a Ph.D. in Biophysical Chemistry and Molecular Structure at the Massachusetts Institute of Technology (MIT). Isaac’s discoveries led to several publications in top journals, including Science and Cell, and were selected by Science as one of the “2003: Signaling Breakthroughs of the Year”. These discoveries also resulted in four issued patents. While at MIT, Isaac also completed several business classes at the Sloan School of Management.
Managing Director, MPM Capital
Jim Scopa is a Managing Director in MPM's San Francisco office, having joined the firm in 2005. Previously, Mr. Scopa served as the Co-Director of Health Care Investment Banking at Thomas Weisel Partners from June 2002 to May 2005, and as the Managing Director and Global Co-Head of Healthcare Investment Banking at Deutsche Banc Alex. Brown & Sons from June 1999 to February 2002. He serves as a director on the board of Conatus Pharmaceuticals Inc., a publicly traded biotechnology company and served on the board of TriVascular, Inc., a publicly traded pharmaceutical company that was sold to Endologix, Inc. Mr. Scopa received an A.B. from Harvard College, an M.B.A from Harvard Business School and a J.D. from Harvard Law School.
Dr. Beth Seidenberg
Partner, Kleiner Perkins Caufield & Byers
Beth Seidenberg joined Kleiner Perkins Caufield & Byers in May 2005 to work in the life sciences area. For the past 20 years, she has focused her career on introducing new innovative treatments for AIDS, arthritis, asthma, cancer, psoriasis, cardiovascular, metabolic, neurological and renal disorders. She introduced 10 innovative products to market and achieved over 40 regulatory approvals (including new indications and formulations) on a worldwide basis. These products have been successfully commercialized and have generated several billion dollars of revenue. Prior to joining KPCB, Beth was Senior Vice President, Global Development, and Chief Medical Officer at Amgen, Inc., the world’s largest biotechnology company. During Beth’s three years there, her responsibilities included: all stages of clinical research, regulatory affairs, safety, health economics/reimbursement and medical affairs. Prior to joining Amgen, Beth was a senior executive in research and development at Bristol-Myers Squibb Company and Merck & Co., Inc. She began her career in basic and clinical research at the National Institutes of Health specializing in immunology and infectious diseases. Beth received her BS from Barnard College magna cum laude, Phi Beta Kappa; and her medical degree from the University Of Miami School Of Medicine, alpha omega alpha. Her post-graduate training was completed at Johns Hopkins, George Washington School of Medicine and the National Institutes of Health.
Dr. Nancy Stagliano
Chief Executive Officer
Nancy Stagliano, Ph.D. is currently Chief Executive Officer and co-founder of True North Therapeutics, a rare disease therapeutics company working in the classical complement pathway. Dr. Stagliano has an accomplished career as a biotech leader spanning all aspects of the industry, from company building, discovery research and strategy to global medical affairs and corporate communications. Previously, Dr. Stagliano was CEO of iPierian, Inc. which applied human iPSCs to model neurodegenerative diseases. The company and its lead antibody program against Tau for the treatment of PSP and Alzheimer’s disease was acquired by BMS in April of 2014 for a total deal value of $725M. Nancy was the CEO and co-founder of CytomX Therapeutics and a lead inventor on the patents for CytomX’s Probody platform. In earlier roles with CytomX, she served as the COO of CytomX LLC, which launched CytomX Therapeutics as well as Cynvenio Biosystems. Before moving to California, Nancy joined the Cambridge, Massachusetts, biotechnology industry in the late 1990s, where she had an eight-year tenure at Millennium Pharmaceuticals and consulted to several local startups. Dr. Stagliano received her BS in Electrical Engineering and her MS in Biomedical Engineering, both from Drexel University in Philadelphia. She obtained her PhD in Neuroscience from the University of Miami, followed by three years as an independently-funded research fellow at the Massachusetts General Hospital and Harvard Medical School, where she studied mechanisms of brain injury after stroke.
Dr. Peter Van Vlasselaer
Peter Van Vlasselaer, Ph.D. served as iPierian’s Interim CEO from April to August 2011, and has served as iPierian’s Executive Chairman since September 2011. He has over 20 years of experience in the industry and has been involved in the start-up of four biotechnology companies. Most recently he was the founding CEO of Arresto Biosciences which was acquired by Gilead Sciences in December 2010. Previously, Peter was the CEO of Avidia, Inc. from May 2004 until it was acquired by Amgen in October 2006. Prior to that he was involved in the start-up of InterMune where he served as Senior VP of Technical operations from November 1999 until May 2004. In 1993, he was involved in the start-up of Dendreon where he served as Vice President of Development until 1999. Between 1990 and 1993, Dr. Van Vlasselaer was a staff scientist at the Center for Nuclear Energy in Mol, Belgium. To date he has contributed to the development of several small molecule and biologic products in therapeutic areas such as cancer, inflammation, infectious diseases and fibrosis. Dr. Van Vlasselaer obtained a bachelor degree in zoology and a PhD in immunology from the University of Leuven in Belgium. He conducted post-doctoral research at Stanford University and at DNAX Research Institute in Palo Alto, CA. He has authored several peer reviewed scientific articles and book chapters and is the inventor on more than 30 patents.